Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02595996 · ClinicalTrials.gov registry record · Phase 2
Propranolol Dose Escalation in Lymphedema in Patients
A Phase 2 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02595996 is a Phase 2 study that was terminated before completion, run by Columbia University. The registered enrollment target is 1 participants.
The verdict
NCT02595996, a Phase 2 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a study to investigate the safety and efficacy of propranolol in the treatment of patients with primary lymphedema. The primary goal is to assess patient tolerability of increasing doses of propranolol. The secondary goal is to assess lymphedema symptoms and signs in response to propranolol treatment.
Interventions
- DRUG Propranolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-06-07 |
| Est. Completion | 2020-10-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02595996
The ClinicalTrials.gov registry entry for NCT02595996 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Propranolol is the first listed.
NCT02595996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02595996 about?
NCT02595996 is a clinical study titled "Propranolol Dose Escalation in Lymphedema in Patients". This is a study to investigate the safety and efficacy of propranolol in the treatment of patients with primary lymphedema. The primary goal is to assess patient tolerability of increasing doses of propranolol. The secondary goal is to assess lymphedema symptoms and signs in response to propranolol ...
What is the current status of trial NCT02595996?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2017-06-07. Estimated completion is 2020-10-08.
What interventions are being tested in trial NCT02595996?
The interventions under investigation include: Propranolol (DRUG).
Who is sponsoring clinical trial NCT02595996?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.